382 related articles for article (PubMed ID: 31544862)
1. Factors Affecting the Pharmacology of Antibody-Drug Conjugates.
Lucas AT; Price LSL; Schorzman AN; Storrie M; Piscitelli JA; Razo J; Zamboni WC
Antibodies (Basel); 2018 Feb; 7(1):. PubMed ID: 31544862
[TBL] [Abstract][Full Text] [Related]
2. Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents.
Lucas AT; Madden AJ; Zamboni WC
Expert Opin Drug Metab Toxicol; 2015; 11(9):1419-33. PubMed ID: 26173794
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.
Lucas AT; Robinson R; Schorzman AN; Piscitelli JA; Razo JF; Zamboni WC
Antibodies (Basel); 2019 Jan; 8(1):. PubMed ID: 31544809
[TBL] [Abstract][Full Text] [Related]
4. Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist's Perspective.
Lucas AT; Moody A; Schorzman AN; Zamboni WC
Antibodies (Basel); 2021 Jul; 10(3):. PubMed ID: 34449544
[TBL] [Abstract][Full Text] [Related]
5. Complex effects of tumor microenvironment on the tumor disposition of carrier-mediated agents.
Lucas AT; Price LS; Schorzman A; Zamboni WC
Nanomedicine (Lond); 2017 Aug; 12(16):2021-2042. PubMed ID: 28745129
[TBL] [Abstract][Full Text] [Related]
6. Challenges in preclinical to clinical translation for anticancer carrier-mediated agents.
Lucas AT; Madden AJ; Zamboni WC
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Sep; 8(5):642-53. PubMed ID: 26846457
[TBL] [Abstract][Full Text] [Related]
7. Complex Factors and Challenges that Affect the Pharmacology, Safety and Efficacy of Nanocarrier Drug Delivery Systems.
Piscatelli JA; Ban J; Lucas AT; Zamboni WC
Pharmaceutics; 2021 Jan; 13(1):. PubMed ID: 33477395
[TBL] [Abstract][Full Text] [Related]
8. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
Vezina HE; Cotreau M; Han TH; Gupta M
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
Khera E; Thurber GM
BioDrugs; 2018 Oct; 32(5):465-480. PubMed ID: 30132210
[TBL] [Abstract][Full Text] [Related]
10. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
Yamada K; Ito Y
Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacology of Antibody-Drug Conjugates.
Mahmood I
Antibodies (Basel); 2021 May; 10(2):. PubMed ID: 34063812
[TBL] [Abstract][Full Text] [Related]
12. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
13. Methods and Study Designs for Characterizing the Pharmacokinetics and Pharmacodynamics of Carrier-Mediated Agents.
Schorzman AN; Lucas AT; Kagel JR; Zamboni WC
Methods Mol Biol; 2018; 1831():201-228. PubMed ID: 30051434
[TBL] [Abstract][Full Text] [Related]
14. ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates.
Mou S; Huang Y; Rosenbaum AI
Antibodies (Basel); 2018 Nov; 7(4):. PubMed ID: 31544891
[TBL] [Abstract][Full Text] [Related]
15. Antibody drug conjugates - Trojan horses in the war on cancer.
Iyer U; Kadambi VJ
J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates: Possibilities and Challenges.
Nejadmoghaddam MR; Minai-Tehrani A; Ghahremanzadeh R; Mahmoudi M; Dinarvand R; Zarnani AH
Avicenna J Med Biotechnol; 2019; 11(1):3-23. PubMed ID: 30800238
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
19. Development of and insights from systems pharmacology models of antibody-drug conjugates.
Lam I; Pilla Reddy V; Ball K; Arends RH; Mac Gabhann F
CPT Pharmacometrics Syst Pharmacol; 2022 Aug; 11(8):967-990. PubMed ID: 35712824
[TBL] [Abstract][Full Text] [Related]
20. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
